<DOC>
	<DOCNO>NCT01364012</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety Avastin ( bevacizumab ) versus placebo combination carboplatin/paclitaxel patient advanced recurrent non-squamous non-small cell lung cancer receive prior chemotherapy advance disease . Patients randomize receive either Avastin 15 mg/kg intravenously placebo Day 1 3-week cycle , plus 6 cycle carboplatin/paclitaxel . Anticipated time study treatment disease progression unacceptable toxicity occurs . After progression , patient Avastin-arm may continue receive Avastin combination approve second- third-line treatment discretion investigator , third progression .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Versus Placebo Combination With Carboplatin/Paclitaxel ) Patients With Advanced Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advance ( Stage IIIb amenable combined modality treatment ) , metastatic ( Stage IV ) recurrent nonsquamous nonsmall cell lung cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate haematological , renal liver function Prior chemotherapy treatment another systemic anticancer agent current stage disease ( IIIb , IV recurrent ) Mixed nonsmall cell small cell tumour mix adenosquamous carcinoma predominant squamous component Evidence tumour invade major blood vessel image CNS metastasis , even previously treat History haemoptysis 3 month prior enrollment History evidence inherit bleed diathesis coagulopathy Uncontrolled hypertension and/or history hypertensive crisis hypertensive encephalopathy Clinically significant cardiovascular vascular disease Malignancies NSCLC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer ductal carcinoma situ treat surgically curative intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>